{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T21:50:45Z","timestamp":1791496245062,"version":"4.3.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,2,3]],"date-time":"2021-02-03T00:00:00Z","timestamp":1612310400000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002402","name":"Sun Yat-sen University","doi-asserted-by":"publisher","award":["\u201cFive & Five\u201d project"],"award-info":[{"award-number":["\u201cFive & Five\u201d project"]}],"id":[{"id":"10.13039\/501100002402","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Scientific and Technological Bureau of Guangzhou, Guangdong Province","award":["201508020059"],"award-info":[{"award-number":["201508020059"]}]},{"DOI":"10.13039\/501100013143","name":"National Natural Science Foundation of China-Shandong Joint Fund for Marine Science Research Centers","doi-asserted-by":"publisher","award":["ZR2019MC024"],"award-info":[{"award-number":["ZR2019MC024"]}],"id":[{"id":"10.13039\/501100013143","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>HBV integration is suspected to be an obstinate risk factor for hepatocellular carcinoma (HCC) in the era of antiviral therapy. Integration events start to occur in the immunotolerance phase, but their fates in the immune clearance phase have not yet been clarified. Here, we report the influences of liver damage on HBV integration and clonal hepatocyte expansion in patients with chronic hepatitis B (CHB).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>HBV integration breakpoints in liver biopsy samples from 54 CHB patients were detected using a modified next-generation sequencing assay.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 3729 (69 per sample) integration breakpoints were found in the human genome, including some hotspot genes and KEGG pathways, especially in patients with abnormal transaminases. The number of breakpoint types, an integration risk parameter, was negatively correlated with HBV DNA load and transaminase levels. The average, maximum and total frequencies of given breakpoint types, parameters of clonal hepatocyte expansion, were negatively correlated with HBV DNA load, transaminase levels and liver inflammation activity grade score. The HBV DNA load and inflammation activity grade score were further found to be positively correlated with transaminase levels. Moreover, nucleos(t)ide analog (NUC) treatment that normalized transaminases nonsignificantly reduced the types, but significantly increased the average frequency and negated the enrichments of integration breakpoints.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Liver damage mainly removed the inventories of viral integration and clonal hepatocytes in CHB. NUC treatment may have reduced HBV integration but clearly increased clonal hepatocyte expansion, which may explain why HCC risk cannot be ruled out by NUC treatment.<\/jats:p><\/jats:sec>","DOI":"10.1007\/s12072-020-10125-y","type":"journal-article","created":{"date-parts":[[2021,2,3]],"date-time":"2021-02-03T16:04:06Z","timestamp":1612368246000},"page":"60-70","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Liver damage favors the eliminations of HBV integration and clonal hepatocytes in chronic hepatitis B"],"prefix":"10.1007","volume":"15","author":[{"given":"Gang","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming X.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei Y.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong J.","family":"Gan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen X.","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1971-6298","authenticated-orcid":false,"given":"Xiao M.","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,3]]},"reference":[{"issue":"5","key":"10125_CR1","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1002\/hep.29321","volume":"66","author":"J Choi","year":"2017","unstructured":"Choi J, Han S, Kim N, Lim YS. Increasing burden of liver cancer despite extensive use of antiviral agents in a hepatitis B virus-endemic population. Hepatology. 2017;66(5):1454\u201363.","journal-title":"Hepatology"},{"issue":"5","key":"10125_CR2","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1002\/hep.29320","volume":"66","author":"GV Papatheodoridis","year":"2017","unstructured":"Papatheodoridis GV, Idilman R, Dalekos GN, Buti M, Chi H, Boemmel FV, et al. The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with CHB. Hepatology. 2017;66(5):1444\u201353.","journal-title":"Hepatology"},{"issue":"4","key":"10125_CR3","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1158\/1055-9965.EPI-19-0614","volume":"29","author":"SU Kim","year":"2020","unstructured":"Kim SU, Seo YS, Lee HA, Kim MN, Lee EJ, Shin HJ, et al. Hepatocellular carcinoma risk steadily persists over time despite long-term antiviral therapy for hepatitis B: a multicenter study. Cancer Epidemiol Biomarkers Prev. 2020;29(4):832\u20137.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"Suppl 1","key":"10125_CR4","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/liv.13291","volume":"37","author":"G Grossi","year":"2017","unstructured":"Grossi G, Vigan\u00f2 M, Loglio A, Lampertico P. Hepatitis B virus long-term impact of antiviral therapy nucleot(s)ide analogues (NUCs). Liver Int. 2017;37(Suppl 1):45\u201351.","journal-title":"Liver Int"},{"issue":"8","key":"10125_CR5","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1136\/gutjnl-2014-307023","volume":"64","author":"P Arends","year":"2015","unstructured":"Arends P, Sonneveld MJ, Zoutendijk R, Carey I, Brown A, Fasano M, et al. Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians. Gut. 2015;64(8):1289\u201395.","journal-title":"Gut"},{"issue":"12","key":"10125_CR6","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1111\/jvh.13185","volume":"26","author":"DH Sinn","year":"2019","unstructured":"Sinn DH, Kim SE, Kim BK, Kim JH, Choi MS. The risk of hepatocellular carcinoma among chronic hepatitis B virus-infected patients outside current treatment criteria. J Viral Hepat. 2019;26(12):1465\u201372.","journal-title":"J Viral Hepat"},{"issue":"5","key":"10125_CR7","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1016\/j.jhep.2017.06.019","volume":"67","author":"TC Yip","year":"2017","unstructured":"Yip TC, Chan HL, Wong VW, Tse YK, Lam KL, Wong GL. Impact of age and gender on risk of hepatocellular carcinoma after hepatitis B surface antigen seroclearance. J Hepatol. 2017;67(5):902\u20138.","journal-title":"J Hepatol"},{"key":"10125_CR8","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.3389\/fimmu.2019.02048","volume":"10","author":"Y Chen","year":"2019","unstructured":"Chen Y, Tian Z. HBV-Induced Immune Imbalance in the Development of HCC. Front Immunol. 2019;10:2048.","journal-title":"Front Immunol"},{"issue":"7","key":"10125_CR9","doi-asserted-by":"publisher","first-page":"365","DOI":"10.3390\/genes9070365","volume":"9","author":"MA Budzinska","year":"2018","unstructured":"Budzinska MA, Shackel NA, Urban S, Tu T. Cellular genomic sites of hepatitis B virus DNA integration. Genes (Basel). 2018;9(7):365.","journal-title":"Genes (Basel)"},{"key":"10125_CR10","doi-asserted-by":"publisher","first-page":"12992","DOI":"10.1038\/ncomms12992","volume":"7","author":"LH Zhao","year":"2016","unstructured":"Zhao LH, Liu X, Yan HX, Li WY, Zeng X, Yang Y, et al. Genomic and oncogenic preference of HBV integration in hepatocellular carcinoma. Nat Commun. 2016;7:12992.","journal-title":"Nat Commun"},{"issue":"7","key":"10125_CR11","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/ng.2295","volume":"44","author":"WK Sung","year":"2012","unstructured":"Sung WK, Zheng H, Li S, Chen R, Liu X, Li Y, et al. Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma. Nat Genet. 2012;44(7):765\u20139.","journal-title":"Nat Genet"},{"issue":"5","key":"10125_CR12","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1053\/j.gastro.2016.07.012","volume":"151","author":"WS Mason","year":"2016","unstructured":"Mason WS, Gill US, Litwin S, Zhou Y, Peri S, Pop O, et al. HBV DNA integration and clonal hepatocyte expansion in chronic hepatitis b patients considered immune tolerant. Gastroenterology. 2016;151(5):986-998.e4.","journal-title":"Gastroenterology"},{"issue":"4","key":"10125_CR13","doi-asserted-by":"publisher","first-page":"e317","DOI":"10.1038\/oncsis.2017.22","volume":"6","author":"R Chauhan","year":"2017","unstructured":"Chauhan R, Churchill ND, Mulrooney-Cousins PM, Michalak TI. Initial sites of hepadnavirus integration into host genome in human hepatocytes and in the woodchuck model of hepatitis B-associated hepatocellular carcinoma. Oncogenesis. 2017;6(4):e317.","journal-title":"Oncogenesis"},{"issue":"3","key":"10125_CR14","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1136\/gutjnl-2011-300937","volume":"61","author":"F Zoulim","year":"2012","unstructured":"Zoulim F, Mason WS. Reasons to consider earlier treatment of chronic HBV infections. Gut. 2012;61(3):333\u20136.","journal-title":"Gut"},{"issue":"16","key":"10125_CR15","doi-asserted-by":"publisher","first-page":"8308","DOI":"10.1128\/JVI.00833-10","volume":"84","author":"WS Mason","year":"2010","unstructured":"Mason WS, Liu C, Aldrich CE, Litwin S, Yeh MM. Clonal expansion of normal-appearing human hepatocytes during chronic hepatitis B virus infection. J Virol. 2010;84(16):8308\u201315.","journal-title":"J Virol"},{"issue":"7779","key":"10125_CR16","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/s41586-019-1670-9","volume":"574","author":"SF Brunner","year":"2019","unstructured":"Brunner SF, Roberts ND, Wylie LA, Moore L, Aitken SJ, Davies SE, et al. Somatic mutations and clonal dynamics in healthy and cirrhotic human liver. Nature. 2019;574(7779):538\u201342.","journal-title":"Nature"},{"issue":"9","key":"10125_CR17","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1111\/jvh.12380","volume":"22","author":"T Tu","year":"2015","unstructured":"Tu T, Mason WS, Clouston AD, Shackel NA, McCaughan GW, Yeh MM, et al. Clonal expansion of hepatocytes with a selective advantage occurs during all stages of chronic hepatitis B virus infection. J Viral Hepat. 2015;22(9):737\u201353.","journal-title":"J Viral Hepat"},{"issue":"4","key":"10125_CR18","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.ygeno.2013.07.002","volume":"102","author":"W Li","year":"2013","unstructured":"Li W, Zeng X, Lee NP, Liu X, Chen S, Guo B, et al. HIVID: an efficient method to detect HBV integration using low coverage sequencing. Genomics. 2013;102(4):338\u201344.","journal-title":"Genomics"},{"issue":"16","key":"10125_CR19","doi-asserted-by":"publisher","first-page":"e164","DOI":"10.1093\/nar\/gkq603","volume":"38","author":"K Wang","year":"2010","unstructured":"Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 2010;38(16):e164.","journal-title":"Nucleic Acids Res"},{"issue":"6","key":"10125_CR20","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1182\/blood-2012-08-447839","volume":"122","author":"L Li","year":"2013","unstructured":"Li L, Zhang JA, Dose M, Kueh HY, Mosadeghi R, Gounari F, et al. A far downstream enhancer for murine Bcl11b controls its T-cell specific expression. Blood. 2013;122(6):902\u201311.","journal-title":"Blood"},{"issue":"2","key":"10125_CR21","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/ng.3178","volume":"47","author":"Z Hu","year":"2015","unstructured":"Hu Z, Zhu D, Wang W, Li W, Jia W, Zeng X, et al. Genome-wide profiling of HPV integration in cervical cancer identifies clustered genomic hot spots and a potential microhomology-mediated integration mechanism. Nat Genet. 2015;47(2):158\u201363.","journal-title":"Nat Genet"},{"issue":"5","key":"10125_CR22","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16(5):284\u20137.","journal-title":"OMICS"},{"issue":"1","key":"10125_CR23","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1038\/s41426-018-0145-7","volume":"7","author":"MA Budzinska","year":"2018","unstructured":"Budzinska MA, Shackel NA, Urban S, Tu T. Sequence analysis of integrated hepatitis B virus DNA during HBeAg-seroconversion. Emerg Microbes Infect. 2018;7(1):142.","journal-title":"Emerg Microbes Infect"},{"issue":"11","key":"10125_CR24","doi-asserted-by":"publisher","first-page":"e02007","DOI":"10.1128\/JVI.02007-17","volume":"92","author":"T Tu","year":"2018","unstructured":"Tu T, Budzinska MA, Vondran FWR, Shackel NA, Urban S. Hepatitis B virus DNA integration occurs early in the viral life cycle in an in vitro infection model via sodium taurocholate cotransporting polypeptide-dependent uptake of enveloped virus particles. J Virol. 2018;92(11):e02007-e2017.","journal-title":"J Virol"},{"issue":"2","key":"10125_CR25","first-page":"1410","volume":"19","author":"P Ruan","year":"2019","unstructured":"Ruan P, Dai X, Sun J, He C, Huang C, Zhou R, et al. Different types of viral-host junction found in HBV integration breakpoints in HBV-infected patients. Mol Med Rep. 2019;19(2):1410\u20136.","journal-title":"Mol Med Rep"},{"issue":"4","key":"10125_CR26","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3390\/v9040075","volume":"9","author":"T Tu","year":"2017","unstructured":"Tu T, Budzinska MA, Shackel NA, Urban S. HBV DNA integration: molecular mechanisms and clinical implications. Viruses. 2017;9(4):75.","journal-title":"Viruses"},{"issue":"7","key":"10125_CR27","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1111\/jgh.14075","volume":"33","author":"B Hu","year":"2018","unstructured":"Hu B, Wang R, Fu J, Su M, Du M, Liu Y, et al. Integration of hepatitis B virus S gene impacts on hepatitis B surface antigen levels in patients with antiviral therapy. J Gastroenterol Hepatol. 2018;33(7):1389\u201396.","journal-title":"J Gastroenterol Hepatol"},{"issue":"1 Suppl","key":"10125_CR28","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.jhep.2016.02.016","volume":"64","author":"D Durantel","year":"2016","unstructured":"Durantel D, Zoulim F. New antiviral targets for innovative treatment concepts for hepatitis B virus and hepatitis delta virus. J Hepatol. 2016;64(1 Suppl):S117\u201331.","journal-title":"J Hepatol"},{"issue":"5","key":"10125_CR29","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1016\/j.jhep.2019.06.028","volume":"71","author":"E Gane","year":"2019","unstructured":"Gane E, Verdon DJ, Brooks AE, Gaggar A, Nguyen AH, Subramanian GM, et al. Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: a pilot study. J Hepatol. 2019;71(5):900\u20137.","journal-title":"J Hepatol"},{"issue":"4","key":"10125_CR30","first-page":"112","volume":"26","author":"MG Peters","year":"2019","unstructured":"Peters MG, Hepatitis B. Virus infection: what is current and new. Top Antivir Med. 2019;26(4):112\u20136.","journal-title":"Top Antivir Med"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-020-10125-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12072-020-10125-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-020-10125-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T15:45:23Z","timestamp":1671032723000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12072-020-10125-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["10125"],"URL":"https:\/\/doi.org\/10.1007\/s12072-020-10125-y","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"19 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study has been approved by the ethics committee of the Fifth Affiliated Hospital of Sun Yat-sen University.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from each patient.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Open access"}}]}}